Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates

"The positive NHP results represent a major milestone for Commit Biologics. Not only do they validate that the complement system can be used to safely and effectively deplete cells of interest in a highly relevant model they also demonstrate the ability of our platform to generate novel therapeutics with a unique mechanism of action that can be applied across many different indications,"said Mikkel Wandahl Pedersen, Chief Executive Officer of Commit Biologics. "We are pleased to share these findings at PEGS Europe."

Lisbon, Portugal, 11/11/2025 (informazione.news - comunicati stampa - salute e benessere)

"  "

Commit's Complement Engager technology is designed to redirect and amplify the power of the complement system, a so far underutilized part of the immune system, to selectively kill cells of choice. By combining a conventional antibody with our proprietary complement engager technology, we can generate a highly potent complement activating compound with superior cell depletion capacity. The NHP study establishes critical platform proof-of-concept, showing that complement-driven activity can be harnessed safely and effectively to achieve deep and durable depletion of target cells.

With these results, Commit Biologics has significantly de-risked the BiCE™ modality and opened new possibilities for the development of therapies across multiple indications including immune-mediated and malignant diseases. The company is currently building a pipeline of exciting first in class therapeutics and aim to disclose a first development candidate in 2026.

" ," . "

Bispecific Complement Engagers (BiCEs): Harnessing Complement Activation for Enhanced Antibody Therapy

Mikkel Wandahl Pedersen, PhD, CEO & CSO, Commit Biologics ApS

PEGS Europe , Lisbon Congress Centre, Libson, Portugal

Wednesday November 12 2025, 17:45 GMT

Commit Biologics is a pioneer in guiding the complement system to specifically kill target cells, with applications in autoimmune diseases and cancer. Spun out of Aarhus University, and building on more than three decades of research, Commit's Complement Engager (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. Commit is backed by major investors including Novo Holdings, Bioqube Ventures and Korys.

The complement system is a key component of the innate immune system, acting as one of the body's first lines of defense against infection and disease. It consists of a network of plasma proteins that, once activated, work in concert to recognize, tag, and eliminate pathogens or damaged cells. Beyond its role in host defense, the complement system also influences inflammation, immune regulation, and tissue homeostasis. Harnessing complement activity therefore represents a powerful therapeutic approach with broad potential across autoimmune, inflammatory, and malignant diseases.

View original content:https://www.prnewswire.co.uk/news-releases/commit-biologics-achieves-proof-of-concept-for-novel-complement-engager-platform-in-non-human-primates-302610473.html